文献速递临床试验与 GCP医学人工智能与信息学

通过机器学习个体化制定体外受精/卵胞浆内单精子注射患者首次促卵泡激素剂量:多中心随机对照试验的非劣效性研究方案

Personalizing the first dose of FSH for IVF/ICSI patients through machine learning: a non-inferiority study protocol for a multi-center randomized controlled trial.
PubMed 文献 · Trials · 2024-01-11

这是一项多中心、单盲、随机对照试验方案,计划纳入236例首次接受体外受精和/或卵胞浆内单精子注射的患者,按1:1随机分为干预组(机器学习模型IDoser确定促卵泡激素起始剂量)和对照组(临床医生按标准实践确定剂量)。主要结局为取卵时获取的减数第二次分裂中期卵母细胞数,检验干预组相对对照组的非劣效性;次要结局包括周期取消、卵巢过度刺激综合征风险及首次移植的临床妊娠率和活产率。

要点

  • 方案计划纳入236例首次体外受精/卵胞浆内单精子注射患者,按1:1随机分组。
  • 干预组由机器学习模型IDoser确定促卵泡激素起始剂量,对照组由临床医生按标准实践决定。
  • 主要结局为取卵时获取的减数第二次分裂中期卵母细胞数,采用非劣效性检验。

核心结论

  • 据作者所知,这是首个测试全患者纳入模型选择控制性卵巢刺激首次促卵泡激素剂量的随机试验。
  • 作者指出,医疗领域机器学习模型的前瞻性试验稀缺,但对临床应用是必要的。

研究设计与样本

  • 研究为随机、对照、多中心、单盲临床试验。
  • 研究计划在236例首次周期的体外受精和/或卵胞浆内单精子注射患者中开展,按1:1随机分为两组。
  • 干预组促卵泡激素剂量由名为IDoser的机器学习模型分配,对照组剂量由临床医生按标准实践确定。
  • 根据患者被分类为预期低反应者、高反应者或正常反应者进行分层区组随机化。
  • 患者在研究中的参与在首次胚胎移植结果已知后结束。

主要发现

  • 主要结局为取卵时获取的减数第二次分裂中期卵母细胞数,假设为干预组相对对照组非劣效。
  • 次要结局包括周期取消数(因低反应或未获取成熟卵母细胞)、卵巢过度刺激综合征风险以及每次首次移植的临床妊娠率和活产率。

局限性

  • 原文指出,已提出的控制性卵巢刺激首次促卵泡激素剂量选择模型大多仅在40岁以下排卵正常的女性中开发和测试。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adequately selecting the initial follicle-stimulating hormone (FSH) dose during controlled ovarian stimulation (COS) is key for success in assisted reproduction. The objective of COS is to obtain an optimal number of oocytes to increase the chances of achieving a pregnancy, while avoiding complications for the patient. Current clinical protocols do achieve good results for the majority of patients, but further refinements in individualized FSH dosing may reduce the risk of poor ovarian response while also limiting the risk of ovarian hyperstimulation syndrome (OHSS) risk. Models to select the first FSH dose in COS have been presented in literature with promising results. However, most have only been developed and tested in normo-ovulatory women under the age of 40 years. METHODS: This is a randomized, controlled, multicenter, single blinded, clinical trial. This study will be performed in 236 first cycle in vitro fertilization (IVF) and/or ICSI (intracytoplasmic sperm injection) patients, randomized 1:1 in two arms. In the intervention arm, the dose of FSH will be assigned by a machine learning (ML) model called IDoser, while in the control arm, the dose will be determined by the clinician following standard practice. Stratified block randomization will be carried out depending on the patient being classified as expected low responder, high responder, or normo-responder. Patients will complete their participation in the trial once the first embryo transfer result is known. The primary outcome of the study is the number of metaphase II (MII) oocytes retrieved at ovarian pick up (OPU) and the hypothesis of non-inferiority of the intervention arm compared to the control. Secondary outcomes include the number of cycle cancelations (due to low response or no retrieval of mature oocytes), risk of ovarian hyperstimulation syndrome (OHSS), and clinical pregnancy and live birth rates per first transfer. DISCUSSION: To our knowledge, this is the first randomized trial to test clinical performance of an all-patient inclusive model to select the first dose of FSH for COS. Prospective trials for machine learning (ML) models in healthcare are scarce but necessary for clinical application. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05948293 . Registered on 14 July 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Correa N, Cerquides J, Arcos JL, et al. Personalizing the first dose of FSH for IVF/ICSI patients through machine learning: a non-inferiority study protocol for a multi-center randomized controlled trial. Trials. 2024. PMID: 38212837. doi:10.1186/s13063-024-07907-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。